Merck Expects Underlying Operating Expenses To Increase Mid- To High-Single Digits Next Year; For Keytruda Expecting Moderating Growth As We Approach Peak Revenues For Certain Approved Indications; For Keytruda, Expecting German Market To Be Impacted By Policy Dynamics; Expecting Keytruda & Winrevair Benefit To Fully Unwind In Q4; Majority Of Vaccines Benefit, Primarily Gardasil, To Unwind In 2027